Jos Jonkers
Jos Jonkers is an expert in Oncology at Antoni van Leeuwenhoek Hospital (Netherlands). As of September 2026, ScienceLeadR ranks Jos Jonkers in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Jos Jonkers has authored 486 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 1 of them ongoing. SLR score: 1,864 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Genetics - Biochemistry - Medical Imaging
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2026
Number : 486
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| The anion channel GPR89 is a tumor-specific dependency in breast cancer. PMID 42773111 — cells, proton-translocating atpases, breast neoplasms, biological science disciplines, stress, physiological, neoplasms, breast, dependency, psychological | Nat Commun | 2026 | 0 |
| PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer. PMID 42768030 — cells, recombination, genetic, homologous recombination, breast neoplasms, stress, physiological, neoplasms, breast | Nat Commun | 2026 | 0 |
| The BRCA1 coiled-coil domain is dispensable for suppression of tandem duplications and tolerance of FANCM loss. PMID 42760352 — cells, microscopy, electron, scanning transmission, neoplasms, exons, carcinogenesis, genes, brca1 | EMBO J | 2026 | 1 |
| Beyond the traditional dish: advanced 3D ex vivo culture platforms for tumor modelling. PMID 42497973 — cells, neoplasms, precision medicine, research, tissues, cell culture techniques, tumor microenvironment | Semin Cancer Biol | 2026 | 0 |
| The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy. PMID 42440368 — cells, poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, dna-directed dna polymerase, neoplasms, poly adenosine diphosphate ribose, therapeutics, dna | Clin Cancer Res | 2026 | 2 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of ART6043 in Advanced Metastatic Solid Tumors Patients (POLKA) NCT05898399 — epidermal growth factor, growth, poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, safety, breast neoplasms, dna-directed dna polymerase, neoplasms, multiple chronic conditions, ribose, poly adenosine diphosphate ribose, adenosine, neoplasm metastasis, receptors, growth factor, breast, adenosine diphosphate, adenosine diphosphate ribose, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map